Precision BioSciences Stock Forecast, Price & News

+0.06 (+0.56 %)
(As of 06/23/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume580,887 shs
Average Volume855,662 shs
Market Capitalization$615.04 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive DTIL News and Ratings via Email

Sign-up to receive the latest news and ratings for Precision BioSciences and its competitors with MarketBeat's FREE daily newsletter.

Precision BioSciences logo

About Precision BioSciences

Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1/2a clinical trial, an allogeneic anti-CD19 CAR T cell product candidate for the patients with relapsed or refractory, or R/R, non-Hodgkin lymphoma, or NHL, or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; and PBCAR20A, that is in Phase 1/2a clinical trial, an allogeneic anti-CD20 CAR T therapy for the treatment NHL, chronic lymphocytic leukemia, and small lymphocytic lymphoma, as well as developing PBCAR269A, which is in Phase 1/2a clinical trial, an allogeneic anti-BCMA CAR T cell product candidate for the treatment of R/R multiple myeloma. The Food segment develops food and nutrition products; and provides technology-centric solutions, Elo life systems, and Elo's technology platform solutions. The company has development and commercial license agreement with Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.40 out of 5 stars

Medical Sector

725th out of 2,105 stocks

Biological Products, Except Diagnostic Industry

103rd out of 198 stocks

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Precision BioSciences (NASDAQ:DTIL) Frequently Asked Questions

Is Precision BioSciences a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Precision BioSciences in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Precision BioSciences stock.
View analyst ratings for Precision BioSciences
or view top-rated stocks.

What stocks does MarketBeat like better than Precision BioSciences?

Wall Street analysts have given Precision BioSciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Precision BioSciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Precision BioSciences' next earnings date?

Precision BioSciences is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Precision BioSciences

How were Precision BioSciences' earnings last quarter?

Precision BioSciences, Inc. (NASDAQ:DTIL) announced its quarterly earnings data on Wednesday, May, 12th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.17. Precision BioSciences had a negative trailing twelve-month return on equity of 159.67% and a negative net margin of 299.85%.
View Precision BioSciences' earnings history

How has Precision BioSciences' stock been impacted by Coronavirus (COVID-19)?

Precision BioSciences' stock was trading at $6.49 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, DTIL shares have increased by 64.9% and is now trading at $10.70.
View which stocks have been most impacted by COVID-19

What price target have analysts set for DTIL?

4 Wall Street analysts have issued 1-year price objectives for Precision BioSciences' stock. Their forecasts range from $14.00 to $27.00. On average, they anticipate Precision BioSciences' stock price to reach $20.25 in the next twelve months. This suggests a possible upside of 89.3% from the stock's current price.
View analysts' price targets for Precision BioSciences
or view top-rated stocks among Wall Street analysts.

Who are Precision BioSciences' key executives?

Precision BioSciences' management team includes the following people:
  • Mr. Matthew R. Kane, Co-Founder, CEO, Pres & Director (Age 44, Pay $733.53k)
  • Dr. David S. Thomson Ph.D., Chief Operating Officer (Age 60, Pay $571.82k)
  • Dr. Christopher R. Heery, Consultant (Age 41, Pay $587.38k)
  • Dr. Jefferson J. Smith Ph.D., Co-Founder & CTO
  • Mr. John Alexander Kelly, Interim Chief Financial Officer (Age 54)
  • Mr. Shane Barton, VP, Corp. Controller & Interim Principal Accounting Officer (Age 51)
  • Dr. Derek Jantz Ph.D., Co-Founder, Chief Scientific Officer & Director (Age 45)
  • Mr. Dario Scimeca, Gen. Counsel & Sec. (Age 46)
  • Mr. Bruce Stevens, VP of Quality & Compliance
  • Ms. Heather King, Director of Marketing Communications & PR

What is Matt Kane's approval rating as Precision BioSciences' CEO?

12 employees have rated Precision BioSciences CEO Matt Kane on Matt Kane has an approval rating of 100% among Precision BioSciences' employees. This puts Matt Kane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Precision BioSciences' key competitors?

What other stocks do shareholders of Precision BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precision BioSciences investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), Alector (ALEC), Kaleido Biosciences (KLDO), Gossamer Bio (GOSS), Micron Technology (MU), Homology Medicines (FIXX), Heron Therapeutics (HRTX), Inovio Pharmaceuticals (INO) and Invitae (NVTA).

When did Precision BioSciences IPO?

(DTIL) raised $126 million in an initial public offering (IPO) on Thursday, March 28th 2019. The company issued 7,900,000 shares at $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays acted as the underwriters for the IPO.

What is Precision BioSciences' stock symbol?

Precision BioSciences trades on the NASDAQ under the ticker symbol "DTIL."

Who are Precision BioSciences' major shareholders?

Precision BioSciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.36%), Geode Capital Management LLC (1.26%), Price T Rowe Associates Inc. MD (1.10%), Morgan Stanley (0.94%), Millennium Management LLC (0.89%) and Northern Trust Corp (0.87%). Company insiders that own Precision BioSciences stock include Christopher Heery, David S Thomson, Derek Jantz and Matthew R Kane.
View institutional ownership trends for Precision BioSciences

Which major investors are selling Precision BioSciences stock?

DTIL stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Adams Chetwood Wealth Management LLC, Credit Suisse AG, Alliancebernstein L.P., Northern Trust Corp, Thomasville National Bank, Goldman Sachs Group Inc., and Los Angeles Capital Management LLC. Company insiders that have sold Precision BioSciences company stock in the last year include David S Thomson, Derek Jantz, and Matthew R Kane.
View insider buying and selling activity for Precision BioSciences
or view top insider-selling stocks.

Which major investors are buying Precision BioSciences stock?

DTIL stock was bought by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Morgan Stanley, Citigroup Inc., Rafferty Asset Management LLC, Ghost Tree Capital LLC, UBS Group AG, BlackRock Inc., and Voloridge Investment Management LLC.
View insider buying and selling activity for Precision BioSciences
or or view top insider-buying stocks.

How do I buy shares of Precision BioSciences?

Shares of DTIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Precision BioSciences' stock price today?

One share of DTIL stock can currently be purchased for approximately $10.70.

How much money does Precision BioSciences make?

Precision BioSciences has a market capitalization of $615.04 million and generates $24.28 million in revenue each year. The company earns $-109,010,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis.

How many employees does Precision BioSciences have?

Precision BioSciences employs 231 workers across the globe.

What is Precision BioSciences' official website?

The official website for Precision BioSciences is

Where are Precision BioSciences' headquarters?

Precision BioSciences is headquartered at 302 EAST PETTIGREW STREET SUITE A-100, DURHAM NC, 27701.

How can I contact Precision BioSciences?

Precision BioSciences' mailing address is 302 EAST PETTIGREW STREET SUITE A-100, DURHAM NC, 27701. The company can be reached via phone at 919-314-5512 or via email at [email protected]

This page was last updated on 6/24/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.